FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2073829649> ?p ?o ?g. }

• W2073829649 abstract "Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FLThe BH3 mimetic chemical antagonist obatoclax (GX15-070, Gemin X Pharmaceuticals) has been used in vitro and nowadays also in clinical trials for its potential therapeutic effects in both solid and lymph node malignancies. The effects of obatoclax treatment alone or in combination with cytotoxic drugs results in the reversal of tumor cell resistance. Studies by us and others have reported that inhibition of over expressed anti-apoptotic gene products such as Bcl-2 and Bcl-XL can reverse resistance to TRAIL. Obatoclax was shown to sensitize TRAIL-resistant solid tumors to TRAIL-apoptosis, inhibiting diverse anti-apoptotic molecules like Bcl-2, Bcl-XL and Mcl-1 through direct binding. We hypothesized that treatment of B-NHL cell lines with Obatoclax will result in tumor cell sensitization to TRAIL apoptosis by a different mechanism. B-NHL Ramos cell line were treated with different concentrations of Obatoclax (7-28 nM) and TRAIL (2.5-20 ng/ml) resulting in significant potentiation of apoptosis and synergy. Western analysis revealed that treatment with obatoclax resulted in significant inhibition of several members of the Bcl-2 family such as inhibition of Mcl-1, Bcl-XL, XIAP, and cIAP 1/2. In addition, obatoclax dissociated Bak from Mcl-1 as determined by immunoprecipitation. We found that, obatoclax inhibited the expression/activity of several members of the NF-κB pathway including phospho-p65, IKK2, and phosphor-IκB-α. The NF-κB activity inhibition by obatoclax was assessed by EMSA. We examined whether obatoclax-induced sensitization to TRAIL resulted from both signaling of DR4 and DR5. Treatment of Ramos cells with DR4 siRNA or DR5 siRNA and then treated with obatoclax and TRAIL resulted in the sensitization of cells treated with DR4 siRNA but not DR5 siRNA. We have previously reported that DR5 is negatively regulated by the transcription repressor YY1, upstream of NF-κB. We found that obatoclax inhibited YY1 transcription and expression. The direct role of YY1 inhibition by obatoclax in both DR5 upregulation and sensitization to TRAIL was determined in transfected cells with YY1 siRNA. Such cells showed upregulation of DR5 and sensitivity to TRAIL apoptosis. The inhibitory effect of obatoclax on Mcl-1 activity and the Mcl-1 direct role in sensitization was examined by treatment of cells with Mcl-1 siRNA. Such cells reversed their sensitivity to TRAIL-mediated apoptosis. Overall, the present findings reveal a new mechanism of obatoclax-induced sensitization to TRAIL by inhibiting NF-κB and downstream Mcl-1 and YY1. Both Mcl-1 and YY1 play a direct role in tumor cells sensitization to TRAIL mediated apoptosis. The present findings identify several new therapeutic targets modified by obatoclax whose modifications can reverse tumor cell resistance to TRAIL mediated apoptosis.Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3499. doi:10.1158/1538-7445.AM2011-3499" @default.
• W2073829649 created "2016-06-24" @default.
• W2073829649 creator A5008409461 @default.
• W2073829649 creator A5011522973 @default.
• W2073829649 creator A5026819167 @default.
• W2073829649 creator A5055490703 @default.
• W2073829649 creator A5067305483 @default.
• W2073829649 creator A5082889084 @default.
• W2073829649 date "2011-04-15" @default.
• W2073829649 modified "2023-10-18" @default.
• W2073829649 title "Abstract 3499: Identification of a novel mechanism by which the BH3 mimetic obatoclax sensitizes non-Hodgkin's lymphoma tumor cells to TRAIL-mediated apoptosis" @default.
• W2073829649 doi "https://doi.org/10.1158/1538-7445.am2011-3499" @default.
• W2073829649 hasPublicationYear "2011" @default.
• W2073829649 type Work @default.
• W2073829649 sameAs 2073829649 @default.
• W2073829649 citedByCount "0" @default.
• W2073829649 crossrefType "proceedings-article" @default.
• W2073829649 hasAuthorship W2073829649A5008409461 @default.
• W2073829649 hasAuthorship W2073829649A5011522973 @default.
• W2073829649 hasAuthorship W2073829649A5026819167 @default.
• W2073829649 hasAuthorship W2073829649A5055490703 @default.
• W2073829649 hasAuthorship W2073829649A5067305483 @default.
• W2073829649 hasAuthorship W2073829649A5082889084 @default.
• W2073829649 hasConcept C185592680 @default.
• W2073829649 hasConcept C190283241 @default.
• W2073829649 hasConcept C203014093 @default.
• W2073829649 hasConcept C2779338263 @default.
• W2073829649 hasConcept C31573885 @default.
• W2073829649 hasConcept C33195913 @default.
• W2073829649 hasConcept C502942594 @default.
• W2073829649 hasConcept C55493867 @default.
• W2073829649 hasConcept C71924100 @default.
• W2073829649 hasConcept C98274493 @default.
• W2073829649 hasConcept C98424977 @default.
• W2073829649 hasConceptScore W2073829649C185592680 @default.
• W2073829649 hasConceptScore W2073829649C190283241 @default.
• W2073829649 hasConceptScore W2073829649C203014093 @default.
• W2073829649 hasConceptScore W2073829649C2779338263 @default.
• W2073829649 hasConceptScore W2073829649C31573885 @default.
• W2073829649 hasConceptScore W2073829649C33195913 @default.
• W2073829649 hasConceptScore W2073829649C502942594 @default.
• W2073829649 hasConceptScore W2073829649C55493867 @default.
• W2073829649 hasConceptScore W2073829649C71924100 @default.
• W2073829649 hasConceptScore W2073829649C98274493 @default.
• W2073829649 hasConceptScore W2073829649C98424977 @default.
• W2073829649 hasLocation W20738296491 @default.
• W2073829649 hasOpenAccess W2073829649 @default.
• W2073829649 hasPrimaryLocation W20738296491 @default.
• W2073829649 hasRelatedWork W1451687136 @default.
• W2073829649 hasRelatedWork W2020742984 @default.
• W2073829649 hasRelatedWork W2040875703 @default.
• W2073829649 hasRelatedWork W2057902579 @default.
• W2073829649 hasRelatedWork W2066244997 @default.
• W2073829649 hasRelatedWork W2067222571 @default.
• W2073829649 hasRelatedWork W2068661277 @default.
• W2073829649 hasRelatedWork W2088371348 @default.
• W2073829649 hasRelatedWork W2103234174 @default.
• W2073829649 hasRelatedWork W2148637644 @default.
• W2073829649 hasRelatedWork W2313521204 @default.
• W2073829649 hasRelatedWork W2366982793 @default.
• W2073829649 hasRelatedWork W2521708580 @default.
• W2073829649 hasRelatedWork W2554949411 @default.
• W2073829649 hasRelatedWork W2564325992 @default.
• W2073829649 hasRelatedWork W2579156720 @default.
• W2073829649 hasRelatedWork W2584724108 @default.
• W2073829649 hasRelatedWork W2594935383 @default.
• W2073829649 hasRelatedWork W3011315464 @default.
• W2073829649 hasRelatedWork W3024124234 @default.
• W2073829649 isParatext "false" @default.
• W2073829649 isRetracted "false" @default.
• W2073829649 magId "2073829649" @default.
• W2073829649 workType "article" @default.